Skip to main content

Advertisement

Figure 2 | Arthritis Research & Therapy

Figure 2

From: Effect of risedronate on joint structure and symptoms of knee osteoarthritis: results of the BRISK randomized, controlled trial [ISRCTN01928173]

Figure 2

Changes in mean values at 12 months from baseline measures in patients with osteoarthritis. Patients were given risodronate (Ris) or placebo. Scores were the weighted composite of the 24 question scores on the visual analogue scale (1 to 100 mm) of the Western Ontario and McMaster Universities (WOMAC) osteoarthritis index or its subscales for pain, stiffness, and physical function. Vertical lines represent standard errors of the mean. P values refer to risedronate (15 mg) vs baseline values.

Back to article page